



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Award ID:
CP130013

Project Title:
Clinical Development and Commercialization of Oncolytic Adenovirus for
Treating Malignant Glioma

Award Mechanism:
Company Commercialization

Principal Investigator:
Tufaro, Frank

Entity:
DNAtrix, Inc.

Lay Summary:

DNAtrix, Inc. is a Texas-based companies developing modified viruses for the treatment of the most aggressive type of brain cancer called glioblastoma. Scientists have modified the common cold virus called adenovirus in 2 specific ways so that it can recognize and kill cancer cells very effectively without harming normal brain. The first product of its kind, called Delta-24-RGD, has just completed its first big test in more than 35 patients with GB at the MD Anderson Cancer Center in Houston. May patients with GB who participated had a remarkable response to the therapy, with evidence of tumor killing and improved survival. Perhaps equally important, there were no safety concerns or side-effects such as those that can arise from chemotherapy. If Delta-24-RGD continues to produce benefits for patients in additional clinical trials, the FDA will support its use for treating this devastating disease. This therapy could have a major impact for patient care in Texas and around the world as there are currently very few therapeutic option for patients if the tumor recurs.